Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Parkinson's Disease

In brief

The purpose of this research study is to test the effect of SYN115 compared to placebo (a "sugar pill" that looks like SYN115 but does not include active drug) on movement during the "on" and "off" states as well as other symptoms that some patients with Parkinson's disease experience. This study will also look at whether or not patients with Parkinson's disease experience "side-effects" with SYN115.

Key facts

Study ID

NCT01283594

Run by

Biotie Therapies Inc.

People needed

420

Starts

2011-03-01

Expected to finish

2012-10-01

Last updated by the study team

2019-01-17

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meet Parkinson's Disease (PD) diagnosis consistent with UK PD diagnostic criteria
• Meet Hoehn and Yahr PD stage
• Good response to levodopa
• Stable regimen of anti-parkinson medications
• Are able to complete a Parkinson's disease diary
• If of childbearing potential(male and female), use an acceptable method of birth control
• Able and willing to sign an IRB/IEC approved informed consent
• Able and willing to understand study requirements, follow study instructions, attend all visits and undergo all planned tests.

You may not qualify if…

• Secondary or atypical Parkinson's
• Neurosurgical intervention for Parkinson's disease
• Treatment with apomorphine
• Treatment with anti-psychotic drugs
• Other abnormal findings on physical or neuro exam or history that in the opinion of the investigator would make subject unsuitable for the study or prejudice safety and efficacy evaluation
• MMSE less than 26
• Subjects with untreated or uncontrolled current episode of major depression
• Receipt of any anti-psychotic drugs greater than 1 month in the past 5 years or any exposure in past year (except for quetiapine at doses <100mg per day)
• Women pregnant or lactating
• History of hepatitis, cholangitis
• Untreated or uncontrolled hypothyroidism or hyperthyroidism
• Drops in blood pressure requiring medication to maintain blood pressure
• Any clinically significant out of range laboratory evaluations
• Known sensitivity to the study medication or its components
• Suicide ideation or type 4 or type 5 on the Columbia suicide severity rating scale
• Finding of malignant melanoma on full body skin exam
• Impulse disorder conditions

Where it is running

• Study site — La Jolla, California, United States
• Study site — Loma Linda, California, United States
• Study site — Los Angeles, California, United States
• Study site — Oxnard, California, United States
• Study site — San Francisco, California, United States
• Study site — Denver, Colorado, United States
• Study site — Manchester, Connecticut, United States
• Study site — New Haven, Connecticut, United States
• Study site — Boca Raton, Florida, United States
• Study site — Gainesville, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Weston, Florida, United States
• Study site — Atlanta, Georgia, United States
• Study site — Augusta, Georgia, United States
• Study site — Boise, Idaho, United States
• Study site — Springfield, Illinois, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Des Moines, Iowa, United States
• Study site — Kansas City, Kansas, United States
• Study site — Lexington, Kentucky, United States
• Study site — Baltimore, Maryland, United States
• Study site — West Bloomfield, Michigan, United States
• Study site — Minneapolis, Minnesota, United States
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.